Evaluating effects of deferoxamine in a rat tibia critical bone defect model

Journal of Orthopaedics

Volumn 11, Issue 1, 2014, Pages 5-9

  Grewal, Bikramjit S ^a   Keller, Benjamin ^b   Weinhold, Paul ^a,b   Dahners, Laurence E ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; Critical bone defect; Deferoxamine

Indexed keywords

CALCIUM SULFATE; DEFEROXAMINE; POLYETHERETHERKETONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DEFECT; BONE RADIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRACTURE HEALING; KIRSCHNER WIRE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; TENSION; TIBIA; TORQUE;

EID: 84897890661     PISSN: None     EISSN: 0972978X     Source Type: Journal    
DOI: 10.1016/j.jor.2013.12.005     Document Type: Article

References (14)

1. Goulet J.A., Senunas L.E., DeSilva G.L., Greenfield M.L. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res Jun 1997, 76-81.
2. Frisoni T., Cevolani L., Giorgini A., Dozza B., Donati D.M. Factors affecting outcome of massive intercalary bone allografts in the treatment of tumours of the femur. J Bone Joint Surg Br Jun 2012, 94:836-841.
3. Axelrad T.W., Einhorn T.A. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev Oct-Dec 2009, 20:481-488.
4. Stewart R., Goldstein J., Eberhardt A., Chu G.T., Gilbert S. Increasing vascularity to improve healing of a segmental defect of the rat femur. J Orthop Trauma Aug 2011, 25:472-476.
5. Hertzberg B.P., Holt J.B., Graff R.D., Gilbert S.R., Dahners L.E. An evaluation of carrier agents for deferoxamine, an up-regulator of vascular endothelial growth factor. J Biomater Appl May 2013, 27(8):1046-1054.
6. Wan C., Gilbert S.R., Wang Y., et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A Jan 15 2008, 105:686-691.
7. Shen X., Wan C., Ramaswamy G., et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res Oct 2009, 27:1298-1305.
8. Miles J.D., Weinhold P., Brimmo O., Dahners L. Rat tibial osteotomy model providing a range of normal to impaired healing. J Orthop Res Jan 2011, 29:109-115.
9. Qu Z.H., Zhang X.L., Tang T.T., Dai K.R. Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. Biochem Biophys Res Commun May 30 2008, 370:332-337.
10. Steinbrech D.S., Mehrara B.J., Saadeh P.B., et al. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. Am J Physiol Cell Physiol Apr 2000, 278:C853-C860.
11. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A Jul 7 1998, 95:7987-7992.
12. Conn G., Bayne M.L., Soderman D.D., et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A Apr 1990, 87:2628-2632.
13. Wang Y., Wan C., Deng L., et al. The hypoxia-inducible factoralpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest Jun 2007, 117:1616-1626.
14. Saadeh P.B., Mehrara B.J., Steinbrech D.S., et al. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol Oct 1999, 277(4 Pt 1):C628-C637.